Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.
Effect of Age on the Pharmacokinetics of Meloxicam in ISA Brown Chickens (*Gallus gallus domesticus*).

*A thesis presented in partial fulfilment of the requirements for the degree of*

**Master of Science**

in

**Physiology**

at Massey University, Palmerston North, New Zealand.

**Megan Gildersleve**

2015
Effect of Age on the Pharmacokinetics of Meloxicam in ISA Brown Chickens (*Gallus gallus domesticus*).

Megan Gildersleve

Abstract

The Non-Steroidal Anti-Inflammatory drug (NSAID) meloxicam has been deemed a safe and effective treatment for numerous inflammatory conditions and injuries from extensive pharmacokinetic and pharmacodynamic studies in various mammalian species. However, there is a lack of meloxicam pharmacokinetic information in avian species. This leads to pharmacokinetic data being extrapolated from mammals in order to administer and treat birds. This often leads to ineffective pain relief or overdoses that can be fatal for birds. Due to this void in literature this study was designed to increase the basic pharmacokinetic knowledge in birds but to also determine if age affects the pharmacokinetics of meloxicam in ISA Brown chickens. Meloxicam was injected intravenously (IV) at 2 mg/kg in 20 healthy ISA Brown chickens (*Gallus gallus domesticus*). One group consisted of 10 ISA brown chickens that were 18 weeks old, the second group consisted of 10 ISA Brown chickens that were 24 months old. Serial blood samples were withdrawn from a catheterised vein from each ISA Brown chicken into a heparinised vial at 0, 10, 20, 30 minutes, 1, 4, 8, 10, 12 hours after the administration of meloxicam.

The pharmacokinetics for ISA Brown chickens were calculated using the non-compartmental model, which was analysed using the mean data from each group of ISA Brown
chickens. The elimination half-life, steady state volume of distribution and mean resident time were significantly higher in the 24 month old ISB Brown chickens compared to the 18 week old ISA Brown chickens. Overall, the results indicate that as an ISA Brown chicken ages the pharmacokinetics of meloxicam show some significant changes in crucial pharmacokinetic parameters. The differences in the pharmacokinetic parameters may ultimately affect the efficacy of meloxicam when treating ‘geriatric’ birds due to possible age-related health issues in the liver and kidneys, which are major organs involved in processing drugs.

KEYWORDS: Meloxicam, non-steroidal anti-inflammatory drugs, ISA Brown chickens, analgesia, pharmacokinetics.
Acknowledgements

Thank you to my supervisor Dr Preet Singh and the technical staff Ty and Antony, who helped me through my master’s project. I want to extend my appreciation to Don, Ed and Collin at the Feed Processing Unit at Massey University, for allowing me to conduct my study at your facilities. A huge thank you to Bradley Horton from The Mathworks, you were an invaluable source of knowledge and encouragement when learning and using Matlab and the Simbiology application.

To my wonderful post graduate friends Brittany, Anna and Geneva. It was your constant support and encouragement that helped me get through this project. Knowing I had you to there to laugh and cry with as we went through similar challenges slowed the insanity from setting in.

To the IVABS administration staff, thank you for helping me with all the academic and administrative matters.

I would like to acknowledge the Massey University Scholarship Committee, Avian research funds, and the Graduate Women Manawatu Charitable Trust for the financial assistance you provided me in order to complete my project.

Finally, the biggest support I have had throughout my time at university is my family. Your prayers, unconditional love and support that you have shown me has been indescribable and treasured.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>AIC</td>
<td>Alkaline Information Criterion</td>
</tr>
<tr>
<td>AA</td>
<td>Arachidonic acid</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the curve</td>
</tr>
<tr>
<td>AUMC</td>
<td>Area under the moment curve</td>
</tr>
<tr>
<td>BIC</td>
<td>Bayesian Information Criterion</td>
</tr>
<tr>
<td>BMR</td>
<td>Basal Metabolic Rate</td>
</tr>
<tr>
<td>C&lt;sub&gt;ib&lt;/sub&gt;</td>
<td>Body (systemic) clearance</td>
</tr>
<tr>
<td>CNS</td>
<td>Central nervous system</td>
</tr>
<tr>
<td>C&lt;sub&gt;p0&lt;/sub&gt;</td>
<td>Concentration at time zero</td>
</tr>
<tr>
<td>COX-1</td>
<td>Cyclooxygenase 1</td>
</tr>
<tr>
<td>COX-2</td>
<td>Cyclooxygenase 2</td>
</tr>
<tr>
<td>CYP</td>
<td>Cytochrome P450</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2a&lt;/sub&gt;</td>
<td>Distribution half-life</td>
</tr>
<tr>
<td>α</td>
<td>Distribution rate constant</td>
</tr>
<tr>
<td>DAD</td>
<td>Diode array detector</td>
</tr>
<tr>
<td>ED</td>
<td>Electrochemical detector</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2b&lt;/sub&gt;</td>
<td>Elimination half-life</td>
</tr>
<tr>
<td>β</td>
<td>Elimination rate constant</td>
</tr>
<tr>
<td>GI</td>
<td>Gastrointestinal</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular filtration rate</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt;</td>
<td>Half-life</td>
</tr>
<tr>
<td>HPLC</td>
<td>High Performance Liquid Chromatography</td>
</tr>
<tr>
<td>IM</td>
<td>Intramuscular</td>
</tr>
<tr>
<td>IT</td>
<td>Intrathecal</td>
</tr>
<tr>
<td>IV</td>
<td>Intravenous</td>
</tr>
<tr>
<td>LC/MS</td>
<td>Liquid chromatography/Mass spectrophotometer</td>
</tr>
<tr>
<td>LOD</td>
<td>Limit of detection</td>
</tr>
<tr>
<td>LLE</td>
<td>Liquid-liquid extraction</td>
</tr>
<tr>
<td>LLD</td>
<td>Lower limit of detection</td>
</tr>
<tr>
<td>LLQ</td>
<td>Lower limit of quantification</td>
</tr>
</tbody>
</table>
MAT - Mean absorption time
MEC – Mean effective concentration
MRT – Mean residence time
$C_{\text{max}}$ - Maximum concentration
NSAIDs – Non Steroidal Anti-inflammatory drugs
OA – Oral administration
$C_p$ – Plasma drug concentration at any time
SPE – Solid phase extraction
SC – Subcutaneous
TXA\textsubscript{2} and TXB\textsubscript{2} – Thromboxane
$C_L$ - Total clearance
$V_{dt}$ – Total volume of distribution
$V_d$ – Volume of distribution
$V_{dc}$ – Volume of distribution, central compartment
$V_{dp}$ – Volume of distribution, peripheral compartment
$V_{ss}$ – Volume of distribution, steady state
List of tables

Table 1: The Discoveries of other early NSAIDs (Brune & Hinz, 2004) ..............................................6

Table 2: The mean ± SD of the pharmacokinetic parameters of meloxicam in various birds’ species in the literature ......................................................................................................................24

Table 3: The life stages of various bird species (Doneley, 2011; Harrison & Lightfoot, 2006) ..................................................................................................................................................65

Table 4: The mean ± SD of pharmacokinetic parameters between elderly patients and young adults when administered piroxicam at 20 mg/kg (Woolf et al., 1983) ........................................76

Table 5: Non-compartmental analysis of meloxicam in 18 week old ISA Brown chickens. Meloxicam was injected at 2 mg/kg intravenously. All of the parameters where calculated from the mean of 10 concentration time curves from the mean pool samples ± SEM ..............................................108

Table 6: Non-compartmental analysis of meloxicam in 24 month old ISA Brown chickens. Meloxicam was injected at 2 mg/kg intravenously. All of the parameters were calculated from the mean of 10 concentration time curves from the mean pool samples ± SEM .................................................................................................................................114

Table 7: Non-compartmental analysis of meloxicam in 18 week old ISA Brown chickens and 24 month old ISA Brown chickens. Meloxicam was injected at 2 mg/kg intravenously. All of the parameters were calculated from the mean of 10 concentration time curves from the mean pool samples ± EM .........................................................117

Table 8: Comparison of the mean ± SD of the pharmacokinetic parameters of meloxicam from this study and with various bird species in the literature .................................................................................123
List of figures

Figure 1: The biosynthesis pathway of the various prostaglandins (PG) from arachidonic acid (AA). The inhibition of COX-1 and COX-2 from the NSAIDS aspirin, indomethacin, ibuprofen, rofecoxib, and celecoxib results in the inhibition of PG’s (Rao & Knaus, 2008)………………………………………………………………………………………………………….9

Figure 2: The structure of the COX-1 and COX-2 isoforms. The catalytic sites for the binding of NSAIDs include Tyrosine - TYR385, Serine - SER530 and Arginine - ARG120. Binding at these sites prevent the transforms of arachidonic acid to PGG2. Note the other amino acid residues are Isoleucine – ILE, Valine – Val, Histidine – His, Phenylalanine – Phe. The structure of each enzyme creates a side pocket - SP and an extra space – ES (Botting, 2010)………………………………………………………………………………..…………………………………..….…….12

Figure 3: The physiological and pathophysiological roles that the COX-2 isoform has within the body (Steinmeyer, 2000..…………………………………………..………………………………………….….12

Figure 4: The relationship of the four pharmacokinetic principles, which influence the effect within the body (pharmacodynamics) (Katzung, Masters, & Trevor, 2009)……………………………………………………………………………………………………………………………………………….34

Figure 5: The metabolism of meloxicam into the four metabolites. The main metabolism pathway of meloxicam produces an intermediate metabolite 5’ hydromethyl meloxicam (AF-UH 1), which is convert to a carboxylic acid metabolite (UH-AC 100 SE) then a o xoacetic metabolite (BI-BO 8032 NA). A smaller pathway converts meloxicam in to another o xoacetic metabolite (DS-AC 2 SE) (Davies & Skjodt, 1999).…………………………….………………..……………41

Figure 6: The three stages which aid in the overall rate of drug eliminated from the renal system (Riviere & Papich, 2009)………………………………………………………………………………………………………………………………………………………42

Figure 7: The anatomical and physiological processes within the mammalian nephron which aid in drug excretion and urine production (Riviere & Papich, 2009)………………………………………………………………………………………………………………………………………………………42

Figure 8: The plasma concentration – time curve broken down into trapezoids which is used to calculate the AUC and AUMC (Riviere & Papich, 2009)………………………………………………………………………………………………………………………………………………………44

Figure 9: Graph showing the method for calculating the half-life on the concentration-time curve using the semi-log plot. The X-axis is the log of concentration (x) and the Y-axis is time (t)(Riviere & Papich, 2009)………………………………………………………………………………………………………………………………………………………49

Figure 10: One-compartment pharmacokinetic model (Riviere, 2001)………………………….55
Figure 11: Two-compartmental pharmacokinetic model, which shows the distribution rate constants from the central compartment (k12) and back to the central compartment (k21) (Harrison & Lightfoot, 2006; Riviere, 2011). 55

Figure 12: The two-compartmental model shown on the semi-log plot of the concentration-time curve (Riviere, 2011). 56

Figure 13: The concentration-time curve demonstrating that from the AUC and AUMC (broken lines) the MRT (the solid arrow) is calculated (Riviere, 2011b). 56

Figure 14: A group of juvenile grey parrots (Doneley, 2011). 66

Figure 15: Adult Grey parrot (Doneley, 2011). 66

Figure 16: A 45 year old Grey parrot (Reavill & Dorrestein, 2010). 66

Figure 17: An avian (Psittaciformes) liver with (rl) right liver, (LL) left liver, (Lu) lung, (h) heart, (p) proventriculus and (v) ventriculus (Ritchie et al., 1999). 67

Figure 18: An avian liver that has severe cirrhosis in a 51 year-old grey parrot (Reavill & Dorrestein, 2010). 67

Figure 19: Normal avian kidneys which include (K1) cranial, (K2) middle, and (K3) caudal kidneys, which also includes (lu) lung, and (o) ovary (Ritchie et al., 1999). 68

Figure 20: Avian kidneys that present with uric acid deposits (gout) which gives the speckled appearance. Anatomy of the image includes k1) cranial, (k2) middle, and (k3) caudal kidneys, also includes (lu) lung, and (t) testicles (Ritchie, Harrison, & Harrison, 1999). 68

Figure 21: The change in body composition in young adults and elderly (Klotz, 2009). 75

Figure 22: Chromatograph showing meloxicam standard solutions from 1 μg/mL to 7.81 ng/mL and blank plasma in mobile phase. 103

Figure 23: Chromatograph showing meloxicam peak after the first 30 minutes of intravenous injection at 2 mg/kg dose rate in 18 week old ISA Brown chickens. 104

Figure 24: Chromatograph showing meloxicam peak between the first hour and eight hours after the intravenous injection at 2 mg/kg dose rate in 18 week old ISA Brown chickens. 105

Figure 25: Chromatograph showing meloxicam peak 10 and 12 hours after the intravenous injection at 2 mg/kg dose rate in 18 week old ISA Brown chickens. The blank bird plasma does not show a retention peak at the same retention time as meloxicam following the same extraction procedure. 106
Figure 26: Semi-log plot of concentration time curve for meloxicam after intravenous administration at 2 mg/kg in 18 week old ISA Brown chickens. Each data point represents mean of 10 chickens ± SEM, and the total of 10 chickens were used in this study.

Figure 27: Chromatograph showing meloxicam peak after the first 30 minutes of intravenous injection at 2 mg/kg dose rate in 24 month old ISA Brown chickens.

Figure 28: Chromatograph showing meloxicam peak between the first hour and eight hours after the intravenous injection at 2 mg/kg dose rate in 24 month old ISA Brown chickens.

Figure 29: Chromatograph showing meloxicam peak 10 and 12 hours after the intravenous injection at 2 mg/kg dose rate in 24 month old ISA Brown chickens. The blank bird plasma does not show a retention peak at the same retention time as meloxicam following the same extraction procedure.

Figure 30: Semi-log plot of concentration time curve for meloxicam after intravenous administration at 2 mg/kg in 24 month old ISA Brown chickens. Each data point represents mean of 10 chickens ± SEM, and the total of 10 chickens were used in this study.

Figure 31: Concentration time curve for meloxicam after intravenous administration at 2 mg/kg in 18 week old ISA Brown chickens and 24 month old ISA Brown chickens. Each data point represents mean of 10 chickens ± SEM, and the total of 10 chickens were used in this study.
To my parents
Andrew and Fiona Gildersleve

I cannot truly express how much your unconditional love and support has meant to me. Throughout this journey you have reminded me of the Lord’s love and grace. And that I can do all things through Him who strengthens me.

To my papa
Late David Henry Pledge

Even though you were not here to see me accomplish this goal. Your passion for science lives on through me, and I hope I have done you proud.
Contents

Chapter One ........................................................................................................................................... 1
General Introduction .......................................................................................................................... 1

1. Non-Steroidal Anti-Inflammatory drugs (NSAIDs) ................................................................. 2
   1.1. History of NSAIDs ...................................................................................................................... 3
   1.2.1. Biosynthesis of prostaglandins .......................................................................................... 7
   1.2.2. COX-1 and COX-2 ............................................................................................................. 10
   1.2.3. Side effects of NSAIDs ...................................................................................................... 13
   1.3. Use of NSAIDs in birds ............................................................................................................ 14
   1.4. Meloxicam pharmacokinetics in birds .................................................................................... 21
   1.5. Allometric scaling ................................................................................................................... 25

2. Pharmacokinetics ......................................................................................................................... 32
   2.1 Pharmacokinetic principles ....................................................................................................... 32
   2.1.1. Absorption .......................................................................................................................... 35
   2.1.2. Distribution .......................................................................................................................... 37
   2.1.3. Metabolism/biotransformation .......................................................................................... 37
   2.1.4. Excretion/elimination ......................................................................................................... 39
   2.2. Pharmacokinetic parameters .................................................................................................. 43
   2.2.1. Area under the curve (AUC) .............................................................................................. 43
   2.2.2. Bioavailability (F) ............................................................................................................. 45
   2.2.3. Volume of distribution (V_d) ............................................................................................ 45
   2.2.4. Clearance (C_l) ................................................................................................................... 46
   2.2.5 Half-life (t1/2) ..................................................................................................................... 47
   2.2.6. Mean residence time (MRT) ............................................................................................. 49

2.3. Compartmental pharmacokinetics ........................................................................................... 50
2.4. Non-compartmental pharmacokinetics .................................................................................... 57
3. Age ................................................................................................................................ 61
  3.1. Aging birds ..................................................................................................................... 61
  3.2. Age-related pharmacology of NSAIDs ........................................................................... 69
  3.3. Pharmacokinetics and age ............................................................................................ 72
4. Chapter One conclusion ................................................................................................ 78
5. Objectives ..................................................................................................................... 81
6. References ..................................................................................................................... 82
Chapter Two ..................................................................................................................... 88
Pharmacokinetics of Meloxicam in ISA Brown Chickens (Gallus gallus domesticus). ....... 88
  6.1 Pharmacokinetics of Meloxicam in ISA Brown Chickens (Gallus gallus domesticus). ..... 89
  6.2 Introduction .................................................................................................................... 91
  6.3. Experiment One: Pharmacokinetics of Meloxicam in 18 week old and 24 month old ISA
      Brown Chickens (Gallus gallus domesticus) ....................................................................... 95
      Study Design .......................................................................................................................... 95
      Drug Administration ........................................................................................................... 96
      Sample collection .............................................................................................................. 96
      Reagents and solutions .................................................................................................... 97
      Sample Analysis ............................................................................................................... 97
      Sample Preparation ......................................................................................................... 98
      Pharmacokinetic analysis ................................................................................................. 99
      Results ............................................................................................................................... 100
      Discussion ......................................................................................................................... 118
      References ....................................................................................................................... 129
Chapter Three .................................................................................................................. 133
General Discussion ......................................................................................................... 133
References ......................................................................................................................... 151